Diligence memo · auto-generated · as of July 2, 2026
Oligasis, LLC
Oligasis, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Oligasis, LLC operates in Biotechnology, based in Palo Alto.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Oligasis, LLC has raised $36M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $34M on 2015-09-08.
Most recent recorded round closed around 2015-09-08.
Valuation (modeled)modeled
Provath models Oligasis, LLC at approximately $1.3B (range $68M–$5.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.88× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 74 months.
Last raise 10.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 18.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 77% of Biotechnology peers (4293 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Alector LLC, Gelesis Inc, Prosetta Biosciences Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.